← Back to Search

Other

OHR/AVR118 for Anorexia

Phase 2
Waitlist Available
Led By Martin Chasen, MBChB
Research Sponsored by Ohr Pharmaceutical Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks
Awards & highlights
No Placebo-Only Group

Summary

The purpose of this study is to determine whether patients with advanced cancers who receive OHR/AVR118 solution for injection into the skin can achieve improvement in quality of life. Based on a previous study in patients with AIDS, possible benefits may include improved appetite and strength; weight gain, improved mood; and decreased fatigue.

Eligible Conditions
  • Anorexia
  • Wasting syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~four weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and four weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Alleviation of multiple cachexia symptoms
Secondary study objectives
Corticotropin

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: OHR/AVR118Experimental Treatment1 Intervention
Experimental Drug

Find a Location

Who is running the clinical trial?

Ohr Pharmaceutical Inc.Lead Sponsor
5 Previous Clinical Trials
392 Total Patients Enrolled
Martin Chasen, MBChBPrincipal InvestigatorOttawa Hospital Cancer Centre
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top